A phase II trial of alpha‐interferon and 5‐fluorouracil in patients with advanced carcinoid and islet cell tumors Academic Article Article uri icon

Overview

MeSH Major

  • Mycosis Fungoides
  • Sezary Syndrome

abstract

  • These results suggest that the combination of 5-FU and alpha-IFN does not have any clear superiority over the individual agents alone; 5-FU appears to reduce patient tolerance of alpha-IFN when given on a daily schedule. Further investigations are needed to identify active agents in the treatment of neuroendocrine malignancies.

publication date

  • January 1994

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19940801)74:3<958::AID-CNCR2820740326>3.0.CO;2-X

PubMed ID

  • 8039124

Additional Document Info

start page

  • 958

end page

  • 61

volume

  • 74

number

  • 3